US Patent

US9617546 — Aptamer therapeutics useful in the treatment of complement-related disorders

Method of Use · Assigned to Archemix LLC · Expires 2027-02-14 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using nucleic acid therapeutics to treat complement-related disorders.

USPTO Abstract

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3673`	—	avacincaptad-pegol-sodium

Patent Metadata

Patent number: US9617546
Jurisdiction: US
Classification: Method of Use
Expires: 2027-02-14
Drug substance claim: Yes
Drug product claim: No
Assignee: Archemix LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.